Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study
Author:
Affiliation:
1. Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA;
2. H. Lundbeck A/S, Valby, Copenhagen, Denmark
Funder
Otsuka Pharmaceutical Development & Commercialization Inc.
Publisher
Informa UK Limited
Subject
General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/03007995.2018.1430220
Reference29 articles.
1. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
2. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder
3. The Cost Consequences of Treatment-Resistant Depression
4. If at First You Donʼt Succeed
5. Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An overview of the efficacy and safety of brexpiprazole for the treatment of schizophrenia in adolescents;Expert Review of Neurotherapeutics;2024-07-05
2. Comparative Efficacy of Dopamine Partial Agonists by Doses for Treatment-Resistant Depression;Journal of Clinical Psychopharmacology;2024-04-19
3. A Real-life Study of Brexpiprazole as an Adjunctive Treatment for Major Depressive Disorder in Asian Patients in Singapore (BADA);Clinical Psychopharmacology and Neuroscience;2024-03-12
4. Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress;Journal of Clinical Psychopharmacology;2024-03
5. Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4;The Canadian Journal of Psychiatry;2024-03-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3